These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3095022)

  • 21. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of the alternative pathway of complement by monosodium urate crystals.
    Fields TR; Abramson SB; Weissmann G; Kaplan AP; Ghebrehiwet B
    Clin Immunol Immunopathol; 1983 Feb; 26(2):249-57. PubMed ID: 6872344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of anaphylatoxin activity related to C3a, by treatment of human serum with the nitrogen nucleophile N2H4 or the chaotrope KSCN.
    von Zabern I; Damerau B; Nolte R; Grünefeld E; Vogt W
    Scand J Immunol; 1985 Dec; 22(6):639-51. PubMed ID: 3937227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of the alternative pathway of complement by monosodium urate monohydrate crystals and other inflammatory particles.
    Doherty M; Whicher JT; Dieppe PA
    Ann Rheum Dis; 1983 Jun; 42(3):285-91. PubMed ID: 6407405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of the alternative pathway of human complement by the extracellular slime glycolipoprotein of Pseudomonas aeruginosa.
    Lambris J; Papamichail M; Ioannidis C; Dimitracopoulos G
    J Infect Dis; 1982 Jan; 145(1):78-82. PubMed ID: 6798132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EDTA-resistant activation of the terminal route of mouse complement after partial precipitation of serum with polyethylene glycol.
    van Dijk H; de Vos Burchart H; van Leeuwen M; Willers JM
    Immunol Lett; 1986 Jun; 12(5-6):281-8. PubMed ID: 3089924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of factor D concentrations on fluid phase C3 activation, lysis of rabbit erythrocytes and solubilization of immune complexes.
    Sturfelt G; Sjöholm AG; Truedsson L
    Immunol Lett; 1989 Feb; 20(3):231-6. PubMed ID: 2714846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cobra complement system: I. The alternative pathway of activation.
    Vogel CW; Müller-Eberhard HJ
    Dev Comp Immunol; 1985; 9(2):311-25. PubMed ID: 3894085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
    Sturtevant JE; Balber AE
    Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of divalent cation chelators and magnesium on activation of the alternative complement pathway by Fusobacterium polymorphum (nucleatum).
    Hawley CE; Falkler WA
    J Periodontal Res; 1979 Sep; 14(5):390-6. PubMed ID: 161780
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of C1s, C1r and properdin in the initiation of the C3b-dependent feedback mechanism of the complement system.
    Johnson U
    Acta Pathol Microbiol Scand C; 1978 Apr; 86(2):73-8. PubMed ID: 696332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complement activation on thiol-modified gold surfaces.
    Liu L; Elwing H
    J Biomed Mater Res; 1996 Apr; 30(4):535-41. PubMed ID: 8847362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternative complement pathway-dependent ingestion of fluolite particles by human granulocytes.
    Arnaout MA; Luscinskas FW; Lionetti FJ; Alper CA; Valeri CR
    J Immunol; 1981 Jul; 127(1):278-81. PubMed ID: 6787126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of the alternative (properdin) pathway by divalent cations.
    Lew FT; Yukiyama Y; Waks HS; Osler AG
    J Immunol; 1975 Sep; 115(3):884-8. PubMed ID: 807649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The human alternative complement pathway: biology and immunopathology of activation and regulation.
    Kazatchkine MD; Nydegger UE
    Prog Allergy; 1982; 30():193-234. PubMed ID: 7041132
    [No Abstract]   [Full Text] [Related]  

  • 37. Equine alternative pathway activation by unsensitized rabbit red blood cells.
    Leid RW; Coley SC; Blanchard DP; Perryman LE
    Vet Immunol Immunopathol; 1985 May; 9(1):71-85. PubMed ID: 4024451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of complement by a series of substituted 2-aryl-1,3-indandiones: interaction with the fifth component of complement.
    Asghar SS; Siddiqui AH; van der Goot H; Timmerman H
    Mol Immunol; 1986 May; 23(5):459-65. PubMed ID: 3748011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the classical pathway of complement by Hageman factor fragment.
    Ghebrehiwet B; Silverberg M; Kaplan AP
    J Exp Med; 1981 Mar; 153(3):665-76. PubMed ID: 7252410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition by lysine and arginine of the conversion of C3 and B in the serum and a purified system.
    Shirahama S; Sugawara Y; Takada Y; Takada A
    Int J Immunopharmacol; 1986; 8(3):269-76. PubMed ID: 3089951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.